Clinical trialNCT03916185TerminatedPhase 1/PHASE2Interventional

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment67Respiratory Syncytial Virus (RSV)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study was to evaluate the safety and immunogenicity of a single dose of the recombinant live-attenuated respiratory syncytial virus (RSV) vaccines, RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, and RSV 276, in RSV-seronegative children 6 to 24 months of age.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Coleen Cunningham, MD
University of California, Irvine
Study Chair
clinicaltrials.gov ↗
Ruth Karron, MD
Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health (JHSPH)
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

David Geffen School of Medicine at Ucla Nichd Crs
Los Angeles, California, United States
University of California, Uc San Diego Crs- Mother-Child-Adolescent Hiv Program
San Diego, California, United States
Univ. of Colorado Denver Nichd Crs
Aurora, Colorado, United States
Emory University School of Medicine Nichd Crs
Atlanta, Georgia, United States
Lurie Children'S Hospital of Chicago (lch) Crs
Chicago, Illinois, United States
Rush Univ. Cook County Hosp. Chicago Nichd Crs
Chicago, Illinois, United States
University of Maryland School of Medicine Center for Vaccine Development Crs
Baltimore, Maryland, United States
the Children'S Mercy Hospital Crs
Kansas City, Missouri, United States
Center for Vaccine Development Crs
St Louis, Missouri, United States
Suny Stony Brook Nichd Crs
Stony Brook, New York, United States
Jacobi Med. Ctr. Bronx Nichd Crs
The Bronx, New York, United States
Duke Vaccine and Trials Unit Crs
Durham, North Carolina, United States
Gamble Center for Clinical Studies Crs
Cincinnati, Ohio, United States
Baylor College of Medicine/ Texas Children'S Hospital Nichd Crs
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboRSV 276 VaccineRSV 6120/ΔNS2/1030s VaccineRSV ΔNS2/Δ1313/I1314L Vaccine

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 Jun 2019
Primary completion: 22 Jan 2024
Completion: 25 Apr 2024
Last update posted: 21 Feb 2025
Registered enrollment: 67
Registry id: NCT03916185

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.